respiratori
virus
repres
common
infect
children
tregon
schwarz
meissner
kou
et
al
healthi
children
usual
caus
upper
respiratori
tract
infect
urti
benign
selflimit
cours
tregon
schwarz
meissner
howev
immunocompromis
host
particularli
undergo
transplant
particularli
vulner
sever
infect
whimbey
et
al
couch
et
al
englund
et
al
englund
kim
et
al
campbel
et
al
furthermor
spectrum
immunocompromis
patient
expand
past
decad
owe
prolong
surviv
variou
malign
advanc
hematopoiet
cell
transplant
hct
englund
englund
et
al
fisher
et
al
diagnost
test
improv
viru
detect
rapidli
burden
infect
clinic
outcom
progress
recogn
englund
et
al
englund
although
respiratori
infect
due
opportunist
infect
uncommon
atyp
organ
commun
respiratori
viru
usual
caus
hospit
patient
englund
et
al
fisher
et
al
respiratori
viral
infect
includ
rna
virus
paramyxovirus
rsv
parainfluenza
hmpv
orthomyxovirus
influenza
picornavirus
rhinoviru
coronavirus
well
dna
virus
adenoviru
bocaviru
polyomavirus
whimbey
et
al
englund
et
al
kim
et
al
rna
virus
among
common
caus
respiratori
infect
immunocompromis
patient
whimbey
et
al
hirsch
et
al
tabl
although
annual
activ
virus
variabl
distinct
pattern
describ
caus
season
outbreak
predominantli
seen
winter
whimbey
et
al
kim
et
al
clinic
present
rang
asymptomat
viral
shed
sever
respiratori
distress
hakim
et
al
fisher
et
al
sever
diseas
depend
intrins
viral
factor
well
patient
characterist
includ
underli
diagnosi
treatment
myelosuppress
hct
bear
highest
morbid
mortal
kim
et
al
hakim
et
al
fisher
et
al
advers
outcom
far
like
immunocompromis
patient
nonimmunocompromis
individu
includ
progress
pneumonia
respiratori
failur
increas
mortal
rate
kim
et
al
immunocompromis
adult
cancer
progress
lrti
rang
develop
pneumonia
mortal
high
hirsch
et
al
renaud
et
al
chemali
et
al
campbel
et
al
hutspardol
et
al
chu
et
al
mortal
associ
respiratori
virus
children
undergo
hct
vari
usual
rang
high
ljungman
et
al
et
al
hutspardol
et
al
although
significantli
lower
adult
mortal
remain
consider
higher
gener
popul
long
term
complic
associ
respiratori
viral
infect
airflow
obstruct
bronchiol
obliteran
develop
hct
lung
transplant
recipi
campbel
et
al
chu
et
al
focu
interest
determin
assess
risk
factor
progress
lrti
goal
detect
patient
might
benefit
intervent
could
prevent
clinic
progress
age
lymphopenia
highdos
total
bodi
irradi
presenc
copathogen
signific
risk
factor
progress
lrti
el
saleebi
et
al
waghmar
et
al
kim
et
al
clinic
score
develop
adult
undergo
hct
healthi
children
rsv
infect
better
predict
sever
shah
et
al
caserta
et
al
howev
former
valid
children
latter
lack
import
featur
surround
particular
sub
group
patient
diagnost
test
respiratori
virus
evolv
tremend
past
sever
year
equal
true
hct
patient
immunocompet
patient
test
modal
util
molecular
amplif
techniqu
larg
supplant
cell
cultur
primari
mean
detect
identifi
virus
clinic
diagnost
sampl
mahoni
mahoni
et
al
antigenbas
detect
use
acut
care
set
typic
show
inferior
sensit
specif
compar
molecular
method
pcr
common
amplif
techniqu
fda
clear
approv
vitro
diagnost
test
avail
commerci
detect
common
respiratori
viral
pathogen
caliendo
tabl
market
singl
analyt
assay
test
detect
influenza
assay
detect
small
number
analyt
exampl
detect
influenza
rsv
broadpanel
test
detect
differ
pathogen
rand
et
al
hammond
et
al
hayden
et
al
popowitch
et
al
salez
et
al
often
latter
also
includ
common
bacteri
agent
infect
molecular
test
gener
high
degre
sensit
specif
much
rapid
time
result
compar
cultur
larger
multiplex
panel
advantag
immunocompromis
popul
even
detect
pathogen
without
avail
specif
antivir
therapi
import
implic
infect
control
potenti
decis
surround
time
transplant
furthermor
symptom
atyp
make
difficult
predict
like
agent
infect
degre
clinic
certainti
highli
sensit
test
rais
numer
question
howev
despit
uncertain
clinic
signific
incid
detect
multivir
infect
tend
increas
use
method
sometim
four
agent
detect
simultan
advent
molecular
test
also
increas
time
detect
viral
shed
often
lengthen
immunocompromis
patient
risk
spread
recurr
period
asymptomat
shed
unknown
quantit
method
note
elsewher
work
may
shed
light
viral
dynam
clinic
implic
asymptomat
shed
inform
await
increas
avail
test
togeth
public
studi
highrisk
popul
sever
author
studi
yield
correl
respiratori
sampl
upper
airway
lower
airway
set
lrti
hakki
et
al
analyz
pair
nasopharyng
np
bronchoalveolar
lavag
fluid
specimen
immunocompromis
adult
patient
respiratori
virus
np
sampl
posit
neg
predict
valu
respect
three
set
np
sampl
neg
bal
posit
hakki
et
al
azadeh
et
al
report
patient
initi
neg
np
wash
posit
bal
sampl
suggest
bal
may
valuabl
concern
lrti
np
wash
neg
azadeh
et
al
particularli
report
sever
group
set
sever
pandem
influenza
infect
mulrennan
et
al
yeh
et
al
lee
et
al
suscept
test
limit
influenza
emerg
univers
resist
iv
iv
adamantan
well
rapid
emerg
oseltamivir
resist
iv
led
increas
effort
close
monitor
drug
resist
renaud
et
al
b
okomoadhiambo
et
al
phenotyp
genotyp
assay
develop
genotyp
method
commonli
use
routin
test
detect
neuraminidas
inhibitor
resist
influenza
virus
clinic
specimen
hirsch
et
al
marjuki
et
al
okomoadhiambo
et
al
laplant
st
georg
tamura
et
al
sever
strategi
suggest
decreas
risk
hospit
transmiss
respiratori
virus
hand
hygien
screen
visitor
respiratori
symptom
educ
healthcar
person
avoid
care
patient
sick
isol
patient
respiratori
symptom
among
wide
strategi
implement
across
institut
dykewicz
tomblyn
et
al
engelhard
et
al
hirsch
et
al
molecular
test
allow
rapid
detect
viral
etiolog
becom
import
tool
guid
prevent
practic
whole
genom
gener
sequenc
emerg
potent
tool
enhanc
outbreak
investig
success
appli
rhinoviru
influenza
rsv
gilchrist
et
al
grening
et
al
kothari
et
al
zhu
et
al
houlihan
et
al
particular
challeng
popul
high
proport
asymptomat
patient
respiratori
viral
infect
whether
isol
absenc
symptom
indic
raad
et
al
waghmar
et
al
quantit
method
may
aid
use
inform
determin
infecti
risk
patient
patient
respiratori
symptom
put
immedi
contact
droplet
isol
st
jude
use
clinic
symptom
viral
etiolog
determin
isol
strategi
stop
isol
patient
infect
due
rhinoviru
enteroviru
coronaviru
unidentifi
etiolog
h
resolut
symptom
retest
need
patient
respiratori
infect
due
rsv
influenza
hmpv
hpiv
requir
resolut
symptom
neg
test
taken
isol
although
advanc
treatment
respiratori
infect
made
manag
viral
infect
popul
remain
challeng
ljungman
et
al
casper
et
al
chemali
et
al
waghmar
et
al
shahani
et
al
treatment
primarili
support
includ
fluid
replac
oxygen
hypoxia
mechan
ventil
necessari
meissner
kou
et
al
bronchodil
may
provid
benefit
meissner
kou
et
al
given
signific
mortal
rate
immunocompromis
host
antivir
therapi
consid
avail
casper
et
al
renaud
englund
hirsch
et
al
waghmar
et
al
shahani
et
al
howev
antivir
option
scarc
limit
influenza
lesser
extent
rsv
tabl
casper
et
al
chemali
et
al
waghmar
et
al
jorquera
tripp
shahani
et
al
addit
adjunct
therapi
intraven
immunoglobulin
ivig
monoclon
antibodi
palivizumab
shown
mix
result
ghosh
et
al
de
fontbrun
et
al
hirsch
et
al
falsey
et
al
sever
antivir
monoclon
antibodi
differ
stage
develop
treatment
respiratori
virus
tabl
rsv
singl
strand
negativesens
rna
viru
within
famili
paramyxovirida
genom
transcrib
produc
protein
n
p
sh
g
f
l
papenburg
boivin
tregon
schwarz
attach
glycoprotein
g
fusion
f
glycoprotein
two
major
glycoprotein
surfac
rsv
control
initi
phase
infect
mclellan
et
al
f
protein
main
target
antivir
develop
howev
g
f
glycoprotein
target
neutral
antibodi
natur
infect
capella
et
al
melero
et
al
tian
et
al
singl
antigen
type
rsv
divid
two
subgroup
b
usual
one
group
predomin
epidem
signific
variant
role
diseas
sever
wellunderstood
hall
et
al
walsh
et
al
devincenzo
respiratori
syncyti
viru
rsv
common
caus
lower
respiratori
tract
infect
children
prematur
infant
infant
cardiac
diseas
sever
immunocompromis
patient
experi
increas
morbid
mortal
domachowsk
rosenberg
devincenzo
et
al
devincenzo
hall
et
al
rsv
infect
resembl
season
pattern
patient
hct
andor
hematolog
diseas
occurr
result
increas
risk
infect
commun
household
contact
nosocomi
transmiss
hall
hall
et
al
singl
center
studi
hakim
colleagu
determin
epidemiolog
respiratori
virus
children
acut
lymphoblast
leukemia
report
rsv
second
common
respiratori
account
episod
respiratori
viral
infect
hakim
et
al
hirsch
et
al
describ
rsv
infect
pediatr
patient
acut
myeloid
leukemia
hirsch
et
al
fisher
et
al
found
rsv
third
common
respiratori
viral
infect
pediatr
patient
undergo
hct
rhv
piv
caus
fatal
rate
fisher
et
al
rsv
lrti
associ
increas
rate
hospit
mortal
sever
risk
factor
describ
rsv
lrti
seo
et
al
chemali
et
al
kim
et
al
elsaleebi
colleagu
found
younger
age
lymphopenia
significantli
associ
rsv
lrti
children
el
saleebi
et
al
hakim
studi
lower
nadir
alc
also
associ
rsv
ltri
hakim
et
al
fact
rsv
compar
viru
like
associ
lrti
account
viral
episod
lrti
hakim
et
al
age
neutropenia
lymphocytopenia
graftvshost
diseas
use
myeloabl
condit
regimen
use
corticosteroid
recent
hct
preengraft
signific
risk
factor
includ
index
develop
investig
univers
texa
md
anderson
cancer
center
categor
patient
prognost
risk
group
shah
et
al
waghmar
et
al
explor
sever
risk
factor
rsv
mortal
patient
undergo
hct
rsv
infect
includ
presenc
rsv
viremia
present
one
third
patient
develop
lrti
neutropenia
mechan
ventil
significantli
associ
rsv
viremia
effect
lymphopenia
steroid
use
observ
cohort
viremia
independ
associ
mortal
treatment
aerosol
ribavirin
associ
improv
outcom
includ
decreas
overal
mortal
mortal
due
respiratori
failur
waghmar
et
al
attempt
correl
viral
load
rsv
diseas
sever
yield
mix
result
devincenzo
devincenzo
et
al
gerna
et
al
franz
et
al
el
saleebi
et
al
walsh
et
al
one
hand
devincenzo
et
al
note
patient
intub
higher
viral
load
higher
viral
load
associ
longer
stay
hospit
buckingham
et
al
devincenzo
buckingham
devincenzo
et
al
howev
studi
found
associ
gerna
et
al
franz
et
al
luken
et
al
fuller
et
al
report
associ
viral
load
diseas
sever
patient
year
age
older
patient
fuller
et
al
inconsist
result
may
due
technic
difficulti
precis
quantifi
viru
load
mucos
surfac
perhap
optim
analysi
may
requir
sampl
sever
day
st
jude
develop
droplet
digit
pcr
assay
quantifi
rsa
rsv
b
respiratori
specimen
initi
clinic
valid
perform
sampl
patient
rsv
infect
rsv
viral
load
significantli
higher
febril
patient
year
old
wherea
statist
differ
note
older
patient
patient
present
either
cough
nasal
congest
significantli
higher
viral
load
compar
patient
present
sign
symptom
higher
viral
load
compar
present
one
symptom
eight
patient
rsv
infect
treat
ribavirin
seven
receiv
inhal
ribavirin
one
receiv
iv
ribavirin
sinc
patient
mechan
ventil
viral
load
upon
complet
treatment
significantli
reduc
data
publish
viral
load
test
rsv
wide
avail
clinic
diagnost
use
fdaapprov
methodolog
current
market
ribavirin
nucleosid
analog
resembl
guanosin
act
inhibit
dehydrogenas
enzym
impair
synthesi
guanosin
triphosph
lead
reduc
cellular
deposit
guanidin
necessari
viral
growth
shahani
et
al
initi
elong
rna
hamper
imped
viral
protein
synthesi
knight
et
al
chemali
et
al
aerosol
ribavirin
fdaapprov
treatment
sever
rsvlrti
hospit
infant
young
children
underli
compromis
condit
prematur
cardiopulmonari
diseas
immunosuppress
chemali
et
al
waghmar
et
al
furthermor
ribavirinbas
antivir
therapi
recommend
european
guidelin
leukemia
patient
hct
recipi
high
risk
complic
hirsch
et
al
shah
et
al
perform
systemat
review
base
mainli
retrospect
studi
found
ribavirinbas
therapi
associ
signific
decreas
progress
urti
lrti
furthermor
ribavirin
alon
combin
immunomodulatori
therapi
improv
mortal
rate
compar
therapi
adult
hct
recipi
shah
chemali
topic
recent
gain
lot
interest
given
increas
price
inhal
ribavirin
per
day
januari
per
day
base
averag
whole
sale
price
chemali
et
al
consequ
rise
treatment
cours
would
cost
respect
howev
oral
formul
per
day
depend
dose
strategi
chemali
et
al
waghmar
et
al
author
suggest
oral
formul
effect
given
low
achiev
plasma
concentr
waghmar
et
al
studi
show
benefit
use
oral
ribavirin
adult
patient
rsv
infect
damlaj
et
al
foolad
et
al
pasikhova
et
al
unansw
question
import
given
differ
cost
two
formul
shah
et
al
adjuv
therapi
rsv
infect
also
controversi
variou
therapi
intraven
immunoglobulin
ivig
rsv
hyperimmunoglobulin
palivizumab
use
treatment
shah
chemali
shah
et
al
waghmar
et
al
shahani
et
al
anim
model
initi
studi
show
benefit
ribavirin
plu
rsv
hyperimmunoglobulin
compar
ribavirin
alon
gruber
et
al
whimbey
et
al
ottolini
et
al
ghosh
et
al
falsey
et
al
howev
product
rsv
ivig
sinc
discontinu
adult
hct
recipi
rsv
pneumonia
uncontrol
studi
suggest
use
combin
therapi
ribavirin
ivig
improv
surviv
whimbey
et
al
ghosh
et
al
howev
combin
use
ribavirin
ivig
support
random
trial
forti
allogen
hct
recipi
rsv
infect
palivizumab
fail
reduc
progress
lrti
mortal
de
fontbrun
et
al
given
question
efficaci
high
cost
palivizumab
ambros
mclaurin
routin
use
discourag
practic
vari
wide
among
institut
institut
ribavirin
recommend
treatment
rsv
urti
lrti
patient
year
old
alc
patient
age
alc
diagnosi
aml
relaps
high
risk
undergo
hct
preexist
sever
heart
lung
diseas
figur
use
palivizumab
part
treatment
consid
ivig
total
ig
mgdl
antivir
rsv
differ
stage
develop
tabl
jorquera
tripp
palivizumab
proven
effect
reduc
sever
rsv
infect
prematur
infant
children
chronic
lung
diseas
aap
b
although
efficaci
palivizumab
assess
random
trial
immunocompromis
prudent
use
palivizumab
popul
may
indic
kassi
et
al
describ
success
control
nosocomi
outbreak
rsv
bone
marrow
transplant
unit
use
palivizumab
reduc
transmiss
rsv
high
risk
group
patient
kassi
et
al
st
jude
palivizumab
administ
monthli
dose
novembermarch
patient
aml
scid
hct
recipi
includ
prehct
condit
month
age
patient
month
age
diagnosi
acut
lymphoblast
leukemia
patient
month
age
receiv
intens
immunosuppress
chemotherapi
rsv
season
consid
prophylaxi
case
case
basi
human
influenza
virus
iv
member
famili
orthomyxovirida
belong
three
genera
contain
singl
antigen
distinct
speci
name
influenza
influenza
b
influenza
c
segment
singl
strand
neg
sens
rna
genom
nicholson
et
al
three
iv
type
distinguish
antigen
differ
nucleoprotein
matrix
protein
two
main
surfac
glycoprotein
hemagglutinin
ha
neuraminidas
na
critic
replic
cycl
pathogenesi
iv
nicholson
et
al
season
preval
influenza
infect
immunocompromis
patient
close
parallel
commun
wide
preval
appiah
et
al
bednarska
et
al
incid
influenza
transplant
recipi
low
howev
influenza
infect
remain
signific
caus
morbid
mortal
patient
weigt
et
al
incid
hct
recipi
rang
nichol
et
al
hakim
et
al
found
influenza
common
viru
pediatr
patient
acut
lymphoblast
leukemia
account
respiratori
infect
cohort
major
patient
present
urti
evid
progress
lrti
pandem
influenza
viru
one
rsv
influenza
b
viru
coinfect
remain
patient
influenza
viru
subtyp
hakim
et
al
clinic
present
influenza
differ
consider
describ
gener
popul
urti
symptom
consist
rhiniti
cough
fever
usual
seen
patient
pneumonia
chemali
et
al
kumar
et
al
less
frequent
patient
present
gastrointestin
neurolog
symptom
ison
hayden
peck
et
al
risk
factor
associ
sever
infect
progress
lrti
describ
includ
lymphopenia
steroid
use
delay
antivir
therapi
ljungman
et
al
martino
et
al
chemali
et
al
khanna
et
al
choi
et
al
initi
antivir
treatment
within
h
symptom
associ
improv
outcom
nichol
et
al
choi
et
al
espinosaaguilar
et
al
tantawi
et
al
report
children
adolesc
differ
cancer
type
present
lrti
necessit
hospit
admiss
respiratori
virus
identifi
patient
major
hematolog
malign
influenza
common
viru
associ
hospit
admiss
influenza
influenza
b
patient
admit
icu
bacteri
coinfect
receiv
oseltamivir
less
sever
clinic
pictur
tantawi
et
al
respiratori
complic
mechan
ventil
associ
mortal
immunocompromis
patient
influenza
infect
latter
rang
relat
direct
viral
pathogenesi
superimpos
bacteri
infect
ljungman
et
al
nichol
et
al
choi
et
al
renaud
campbel
fisher
et
al
pediatr
cancer
patient
antivir
treatment
initi
earli
possibl
even
patient
symptomat
h
sinc
may
benefit
even
delay
therapi
aap
influenza
b
inher
resist
inhibitor
amantadin
rimantadin
influenza
becom
resist
overtim
henc
use
limit
neuraminidas
inhibitor
nai
oseltamivir
zanamivir
peramivir
first
line
prophylaxi
treatment
influenza
b
casper
et
al
fior
et
al
chemali
et
al
oseltamivir
given
mouth
main
side
effect
nausea
vomit
diarrhea
inhal
zanamivir
caus
bronchospasm
use
cautious
patient
chronic
lung
diseas
intraven
zanamivir
avail
compassion
use
peramivir
nai
approv
iv
use
ison
hayden
louie
et
al
b
ison
studi
compar
oseltamivir
peramivir
shown
similar
outcom
howev
efficaci
safeti
peramivir
immunocompromis
patient
need
assess
de
jong
et
al
mutat
confer
resist
nai
pandem
influenza
lead
resist
zanamivir
inhal
formul
success
use
treat
patient
renaud
et
al
fraaij
et
al
waghmar
et
al
especi
import
sinc
immunocompromis
patient
increas
risk
develop
resist
mutant
couturi
et
al
renaud
et
al
c
carr
et
al
hamada
et
al
fraaij
et
al
combin
therapi
poorli
studi
shown
benefit
expert
recommend
increas
dose
oseltamivir
due
concern
poor
absorpt
patient
mucos
graft
vs
host
diseas
howev
benefit
intervent
conclus
demonstr
casper
et
al
watcharananan
et
al
length
therapi
remain
controversi
given
median
time
progress
lrti
potenti
recurr
longer
treatment
cours
day
suggest
popul
khanna
et
al
waghmar
et
al
endonucleas
inhibitor
new
class
antivir
drug
clark
et
al
byrn
et
al
phase
iii
develop
baloxavir
marboxil
xofluza
shionogi
co
ltd
underway
usa
eu
countri
heo
omoto
et
al
xofluza
approv
japan
februari
recent
approv
usa
singl
oral
dose
treatment
influenza
b
viru
infect
patient
year
age
older
fda
main
side
effect
describ
diarrhea
bronchiti
amino
acid
substitut
endonucleas
activ
site
shown
reduc
suscept
influenza
strain
hayden
et
al
studi
need
done
determin
whether
singl
dose
would
appropri
immunocompromis
patient
earli
diagnosi
isol
precaut
critic
prevent
transmiss
postexposur
antivir
chemoprophylaxi
given
immunocompromis
patient
come
close
contact
proven
suspect
case
infecti
period
case
fior
et
al
infecti
period
person
influenza
estim
rang
day
day
develop
symptom
nicholson
et
al
patient
come
contact
case
immunocompet
host
whose
ill
start
day
prior
chemoprophylaxi
necessari
howev
infant
immunocompromis
patient
shed
viru
remain
contagi
longer
period
postexposur
chemoprophylaxi
last
day
last
known
exposur
influenza
immunocompromis
patient
month
age
older
vaccin
soon
possibl
season
influenza
vaccin
ljungman
rubin
et
al
although
immunogen
immunocompromis
patient
variabl
vaccin
respons
lower
gener
popul
studi
show
vaccin
patient
get
influenza
sever
infect
less
compar
unvaccin
patient
engelhard
et
al
machado
et
al
issa
et
al
beck
et
al
highdos
trival
inactiv
influenza
vaccin
elicit
robust
immun
respons
children
cancer
compar
standarddos
vaccin
hakim
et
al
institut
dose
influenza
vaccin
recommend
administ
least
day
apart
vaccin
famili
member
health
care
provid
also
import
measur
prevent
influenza
infect
patient
carr
et
al
hakim
et
al
syke
et
al
parainfluenza
virus
piv
belong
famili
paramyxovirida
structur
similar
rsv
neg
sens
singlestrand
rna
genom
encod
six
common
viral
protein
hemagglutininneuraminidas
hn
f
glycoprotein
promot
viral
attach
fusion
viral
host
cell
membran
hall
henrickson
present
serotyp
human
piv
hpiv
recogn
differ
frequenc
occurr
spectrum
clinic
diseas
epidem
pattern
henrickson
common
serotyp
produc
infect
infect
occur
time
year
howev
spring
summer
peak
activ
hall
henrickson
recent
multicent
studi
aim
defin
epidemiolog
outcom
respiratori
viru
infect
pediatr
hct
recipi
show
piv
second
common
viru
cohort
rvi
associ
allcaus
case
fatal
rate
patient
hpiv
infect
die
fisher
et
al
larg
retrospect
studi
children
diagnos
cancer
found
piv
common
respiratori
viru
incid
median
age
year
patient
hct
recipi
maeng
et
al
patient
present
urti
progress
lrti
median
day
onset
symptom
maeng
et
al
hakim
et
al
found
hpiv
third
common
viral
infect
patient
unlik
rsv
patient
hpiv
cohort
like
present
urti
hakim
et
al
neutropenia
lymphopenia
coinfect
use
steroid
describ
risk
factor
progress
srinivasan
et
al
b
ustun
et
al
seo
et
al
lrti
significantli
associ
mortal
day
initi
diagnosi
overal
mortal
rate
cohort
differ
observ
compar
hct
recipi
nonhct
recipi
maeng
et
al
howev
studi
report
mortal
rate
nichol
et
al
shah
et
al
current
antivir
approv
treatment
hpiv
ribavirin
use
anecdot
sever
case
impact
clinic
outcom
includ
progress
lrti
mortal
chemali
et
al
renaud
englund
use
ivig
improv
surviv
hct
recipi
piv
infect
knight
et
al
shah
et
al
chemali
et
al
waghmar
et
al
shahani
et
al
piv
infect
link
bronchiol
obliteran
syndrom
bo
vilchez
et
al
erard
et
al
treatment
altern
bo
limit
part
due
lack
understand
pathogenesi
furthermor
bo
limit
long
term
surviv
patient
highlight
import
prevent
piv
infect
patient
chaparro
et
al
erard
et
al
although
sever
hospit
outbreak
report
nosocomi
transmiss
significantli
reduc
implement
isol
hand
hygien
disinfect
surfac
current
licens
vaccin
piv
live
attenu
piv
vaccin
develop
preliminari
result
phase
trial
suggest
safe
immunogen
karron
et
al
b
adderson
et
al
human
metapneumoviru
hmpv
singl
strand
neg
sens
rna
envelop
viru
famili
paramyxovirida
genom
organ
similar
rsv
except
viru
attach
enter
host
cell
g
f
protein
two
major
subtyp
b
compos
subgroup
papenburg
boivin
schildgen
et
al
mpv
incid
immunocompromis
host
report
high
incid
hematolog
malign
differ
compar
hct
recipi
although
specif
risk
factor
describ
includ
studi
incid
adult
patient
slightli
higher
children
shah
et
al
hakim
et
al
found
acut
respiratori
infect
identifi
viru
children
due
hmpv
one
patient
develop
lrti
hakim
et
al
hmpv
may
caus
urti
lrti
immunocompromis
patient
asymptomat
viral
shed
describ
patient
usual
present
nasal
congest
cough
sore
throat
fever
howev
lrti
develop
patient
present
progress
pneumonia
hypotens
shock
kamboj
et
al
hopp
et
al
samuel
et
al
seo
et
al
el
chaer
et
al
recent
articl
hmpv
infect
report
vast
major
infect
patient
hematolog
malign
recipi
hct
patient
commun
acquir
infect
present
urti
present
lrti
progress
urti
incid
lrti
review
el
chaer
et
al
risk
factor
associ
lrti
use
steroid
low
lymphocyt
count
earli
onset
infect
hct
lrti
significantli
associ
mortal
rang
studi
high
renaud
et
al
shah
et
al
pasikhova
et
al
current
approv
antivir
therapi
hmpv
sever
attempt
made
evalu
role
antivir
therapi
ribavirin
hmpv
infect
consid
limit
studi
design
given
low
number
patient
studi
show
benefit
antivir
therapi
similar
mortal
rate
compar
patient
get
antivir
treatment
hopp
et
al
shah
et
al
pasikhova
et
al
fusion
inhibitor
monoclon
antibodi
develop
yet
reach
clinic
trial
tabl
ulbrandt
et
al
deffrasn
et
al
rhv
belong
genu
enteroviru
within
famili
picornavirida
includ
three
genet
distinct
group
b
c
singlestrand
posit
sens
rna
virus
genom
encod
one
polypeptid
cleav
four
structur
protein
nonstructur
protein
rhv
antigen
divers
serotyp
identifi
date
greenberg
jacob
et
al
rhinoviru
describ
common
respiratori
pathogen
isol
immunocompromis
children
undergo
hct
loria
et
al
fisher
et
al
incid
high
day
milano
et
al
median
time
first
posit
test
report
day
follow
hct
earli
day
late
day
appar
season
rhv
detect
prolong
viral
shed
common
median
week
milano
et
al
higher
viral
load
initi
present
significantli
associ
prolong
viral
shed
ogimi
et
al
former
studi
thirteen
percent
patient
rhv
infect
respiratori
symptom
time
diagnosi
remain
patient
urt
symptom
four
patient
underw
bal
concern
progress
lrti
two
die
respiratori
failur
milano
et
al
result
agre
studi
seo
et
al
look
transplant
recipi
rhinoviru
infect
cohort
eighti
one
percent
patient
present
urti
patient
low
monocyt
count
oxygen
use
steroid
dose
mgkgday
significantli
increas
risk
lrti
mortal
higher
lrti
vs
seo
et
al
multicent
studi
respiratori
viral
infect
pediatr
hct
recipi
report
caus
fatal
rate
patient
rhv
infect
fisher
et
al
pretranspl
rhinoviru
detect
significantli
associ
increas
mortal
day
campbel
et
al
howev
abandh
et
al
find
differ
icu
admiss
length
hospit
mortal
abandeh
et
al
current
treatment
rhv
infect
consist
support
care
antivir
medic
rhv
investig
tabl
cov
envelop
posit
sens
singl
strand
rna
virus
belong
famili
coronavirida
six
coronavirus
divid
two
genera
infect
human
cov
belong
genu
alphacoronaviru
sever
acut
respiratori
syndrom
sar
cov
middl
east
respiratori
syndrom
mer
cov
member
genu
betacoronaviru
genom
code
two
nonstructur
protein
four
structur
protein
van
der
hoek
greenberg
cov
import
caus
common
cold
gener
popul
limit
inform
clinic
manifest
immunocompromis
host
milano
et
al
describ
epidemiolog
risk
factor
cov
infect
among
hct
recipi
cumul
incid
estim
day
median
time
first
detect
day
rang
day
season
outbreak
common
winter
case
first
detect
decemb
march
median
time
shed
week
milano
et
al
ogimi
et
al
describ
sever
risk
factor
relat
prolong
viral
shed
higher
viral
load
use
steroid
myeloabl
condit
ogimi
et
al
univari
analysi
potenti
risk
factor
show
signific
associ
acquisit
patient
age
gender
underli
diseas
risk
stem
cell
sourc
cmv
serostatu
donor
type
acut
gvhd
condit
regimen
engraft
statu
infect
coronavirus
associ
mortal
cohort
milano
et
al
howev
anoth
group
report
similar
mortal
rate
hct
recipi
observ
virus
rsv
influenza
viru
piv
ogimi
et
al
recent
articl
seattl
children
hospit
look
immunocompromis
nonimmunocompromis
children
hcov
infect
median
age
significantli
higher
immunocompromis
patient
demograph
characterist
similar
viral
coinfect
commonli
seen
nonimmunocompromis
patient
mostli
due
detect
rsv
cov
strain
differ
two
group
common
clinic
present
urti
younger
age
male
sex
presenc
underli
pulmonari
disord
detect
respiratori
copathogen
particularli
rsv
associ
increas
likelihood
lrtd
sever
lrtd
howev
lymphopenia
associ
sever
diseas
cohort
ogimi
et
al
current
treatment
avail
coronavirus
howev
current
vitro
evalu
hcov
therapi
includ
investig
antivir
well
human
monoclon
antibodi
pyrc
et
al
adedeji
et
al
tabl
nucleosid
analog
contain
base
base
analog
link
riboselik
moieti
incorpor
viral
polymeras
stop
polymer
inhibit
replic
jorquera
tripp
aka
lumicitabin
alio
biopharmajanssen
nucleosid
analog
inhibit
polymer
function
l
protein
caus
immedi
chain
termin
rna
synthesi
jorquera
tripp
rsv
experiment
infect
healthi
adult
significantli
associ
rapid
viral
clearanc
greater
reduct
viral
load
improv
clinic
symptom
devincenzo
et
al
sever
fusion
inhibitor
develop
direct
glycoprotein
f
goal
block
viral
entri
cell
line
respiratori
tract
battl
et
al
jorquera
tripp
aka
presatovir
gilead
scienc
oral
rsv
entri
inhibitor
function
alloster
blocker
f
protein
prevent
rsv
entri
block
fusion
process
experi
healthi
volunt
rsv
infect
show
treatment
result
reduct
mucu
weight
symptom
score
viral
load
devincenzo
et
al
similar
result
observ
johnson
johnson
steven
et
al
final
target
nucleoprotein
gain
interest
given
highli
conserv
essenti
viru
assembl
jorquera
tripp
rna
interfer
process
small
interf
rna
sirna
decreas
protein
product
degrad
specif
mrna
healthi
adult
volunt
experiment
infect
rsv
receiv
intranas
alnylam
pharmaceut
show
signific
reduct
rsv
replic
compar
placebo
devincenzo
et
al
monoclon
mab
use
prophylaxi
rsvrelat
hospit
admiss
pediatr
popul
sever
mab
target
differ
epitop
f
protein
develop
rossey
et
al
suptavumab
regeneron
pharmaceut
fulli
human
mab
proven
safeti
toler
healthi
adult
recent
phase
iii
clinic
trial
fail
prevent
rsv
infect
infant
compani
discontinu
develop
medimmun
recombin
human
mab
modifi
fc
region
extend
halflif
day
one
singl
dose
zhu
q
et
al
final
ablynx
inhal
trimer
nanobodi
bind
antigen
site
ii
f
protein
neutral
rsv
b
shown
signific
reduct
viral
load
infant
hospit
rsv
compar
placebo
ablynx
fludas
ansun
biopharma
novel
sialidas
fusion
protein
shown
vitro
activ
toward
influenza
strain
isol
date
includ
shown
oseltamivir
resist
trianabaltz
et
al
b
moss
et
al
phase
ii
clinic
trial
healthi
volunt
show
safeti
toler
effect
reduc
viral
load
group
receiv
compar
placebo
moss
et
al
laninamivir
biota
pharmaceut
alpharetta
ga
usa
longact
nai
administ
via
drypowd
inhal
treatment
influenza
shahani
et
al
doubleblind
random
control
trial
healthi
adult
demonstr
singl
inhal
lanimavir
octon
effect
treatment
influenza
importantli
lanimavir
remain
activ
oseltamivirresist
viru
watanab
et
al
favipiravir
toyama
chemic
tokyo
japan
investig
nucleotid
analog
inhibit
viral
rna
polymeras
influenza
strain
kiso
et
al
sleeman
et
al
two
phase
studi
adult
uncompl
influenza
complet
result
pend
janssen
pharma
titusvil
usa
inhibit
influenza
replic
novel
mechan
involv
block
activ
polymeras
complex
nitazoxanid
romark
laboratori
florida
usa
antiparasit
agent
shown
broad
activ
toward
influenza
includ
well
influenza
b
strain
resist
oseltamivir
rossignol
tilmani
et
al
phase
clinic
trial
compar
nitazoxanid
vs
placebo
show
reduct
clinic
symptom
viral
shed
patient
uncompl
influenza
infect
haffizulla
et
al
sever
ongo
trial
includ
phase
evalu
role
nitazoxanid
children
year
age
older
adult
uncompl
influenza
infect
mab
direct
toward
highli
conserv
ha
stalk
influenza
viru
develop
prophylaxi
treatment
shahani
et
al
paradas
ansun
biopharma
novel
sialidas
fusion
protein
prevent
viral
propag
cleav
sialic
acid
respiratori
epitheli
cell
lead
impair
entri
viru
cell
et
al
chalkia
et
al
chemali
et
al
given
compassion
use
immunocompromis
patient
associ
benefit
chen
et
al
drozd
et
al
waghmar
et
al
ansun
biopharma
complet
multisit
phase
ii
studi
compar
placebo
immunocompromis
patient
parainfluenza
lrti
requir
oxygen
us
food
drug
administr
fda
grant
breakthrough
therapi
design
treatment
lower
respiratori
tract
piv
infect
immunocompromis
patient
biopharma
phase
trial
current
plan
fusion
inhibitor
target
f
protein
demonstr
viral
inhibit
vitro
anim
model
deffrasn
et
al
phase
studi
evalu
safeti
toler
pharmacokintet
aka
lumicitabin
alio
biopharmajanssen
hospit
adult
metapneumoviru
infect
plan
two
mab
mab
medimmun
gaithersburg
md
usa
human
fab
prophylact
therapeut
potenti
ulbrandt
et
al
howev
clinic
studi
yet
perform
vapendavir
aviragen
therapeut
alpharetta
ga
usa
oral
antivir
attach
viral
capsid
prevent
releas
rna
cell
activ
rhv
type
b
shahani
et
al
vapendavir
reduc
clinic
symptom
asthmat
adult
welltoler
seriou
advers
event
report
matz
treatment
coronaviru
requir
broadli
activ
compound
design
quickli
respond
new
zoonot
epidem
pathogen
coronavirus
sever
step
coronaviru
life
cycl
antivir
agent
could
implement
pyrc
et
al
adedeji
et
al
report
differ
strategi
develop
block
viral
entri
sarscov
adedeji
et
al
adopt
transfer
specif
cell
promis
approach
technolog
isol
expans
becom
wide
avail
englund
et
al
gerdemann
et
al
heslop
leen
leen
et
al
baugh
et
al
two
main
limit
immunotherapi
strategi
respiratori
virus
one
except
influenza
knowledg
viral
immunolog
less
complet
cmv
ebv
second
limit
logist
virus
caus
greatest
morbid
earli
post
transplant
period
may
feasibl
gener
ctl
time
cover
period
high
risk
howev
aguayohiraldo
et
al
success
expand
use
piv
specif
cell
aguayohiraldo
et
al
group
gener
hmpv
specif
cell
adopt
transfer
patient
allogen
hct
tzannou
et
al
final
multivirusspecif
lymphocyt
rsv
influenza
shown
promis
result
gerdemann
et
al
immunocompromis
patient
remain
vulner
respiratori
viral
infect
risk
sever
lrti
increas
mortal
common
characterist
hematolog
malign
hct
recipi
bear
burden
virus
age
baselin
diagnosi
use
steroid
lymphopenia
earli
onset
transplant
share
risk
factor
lrti
mortal
higher
viral
load
associ
risk
lrti
studi
earli
diagnosi
help
prevent
spread
virus
prompt
support
measur
antivir
indic
howev
manag
infect
remain
challeng
clinic
symptom
alway
reliabl
progress
lrti
happen
within
day
onset
symptom
addit
patient
prolong
viral
shed
make
clinic
evolut
molecular
test
insuffici
guid
length
therapi
persist
posit
test
often
lead
concern
resist
viral
strain
given
high
within
host
viral
diversif
occur
patient
limit
antivir
option
avail
mostli
influenza
extent
rsv
problem
highlight
need
object
biomark
could
help
guid
therapi
standard
valid
assay
assess
viral
load
provid
unbias
reproduc
measur
could
univers
appli
manag
respiratori
viral
infect
immunocompromis
patient
immun
monitor
assay
assess
produc
cell
specif
antigen
gain
interest
field
system
viral
infect
set
object
valid
tool
relat
hostvir
interact
viral
load
specif
immun
respons
could
lead
paramet
significantli
impact
decis
make
approach
monitor
therapeut
option
immunocompromis
patient
respiratori
viral
infect
earli
object
predictor
advers
outcom
could
identifi
children
highest
risk
lrti
death
direct
treatment
specif
timeli
manner
current
possibl
potenti
benefit
increas
pediatr
surviv
rh
serv
advisori
board
roch
molecular
abbott
molecular
quidel
remain
author
declar
research
conduct
absenc
commerci
financi
relationship
could
constru
potenti
conflict
interest
